R&D Experimental Services: Discovery and Preclinical Research

Outsourcing R&D with Labtoo

The life cycle of drug development is extremely long and tedious: it has to undergo many complex and regulated phases in order to ensure its safety, efficacy, and quality for the patients. Pharmaceutical and biotech companies are facing increasing challenges and must identify solutions to respond to these new problems. 

Lately, biotechnology companies tend to outsource their R&D projects and thus have included the use of services providers into their financial models for several reasons. On one hand, biotech companies have often limited financial resources as well as they do not have systematically the technological resources to perform all their projects in-house. Time is also a critical issue in the survival of a small company. Relaying steps of your studies to a specialized R&D services provider able to rapidly achieve a project could be therefore a wise choice.

This is why Labtoo developed a unique solution to support Labs, Biotechs, Medtechs and Pharmaceutical companies in their R&D outsourcing management

 

Our Experimental Services for Research and Development in Biotechnologies

 

We are specialized in tailor-made projects for the pharmaceutical and biotech industry.

Select your options and start building your project.

R&D mecanism Labtoo 200

What is included in our services?

Our team will handle your R&D service management from the beginning to the end

Perform a feasibility study by looking for existing expertise available within the network of partners


Set up a study protocole, financial quotation and preparing contracts with lab partners


Implement the study plan into a schedule, collect all needed materials and reagents and execute the service

Do you need more information about our experimental services?

How are the service providers selected?

 
At Labtoo, we have built a network of 500 service providers from academia, hospitals and private companies. 
 
We are very closely with our customers to understand exactly what is needed: is it a strong expertise on a scientific domain, or a technological requirement, or a little bit of both.
 
We have developed a unique method to qualify and select the best partner for each project
 
During the feasibility study that we carry out with our customers, we will ask a series of questions that will allow us to move forward in full confidence.
 

Selecting the right structure type

When looking for a CRO, there are several choices: generalist or specialized CRO, small or large structure, well-known or not... While a large CRO recognized internationally instills confidence and allows more flexibility, small and medium-sized CROs in France or Europe offer a tailor-made and highly specialized service (cancerology, neurology, cardiology, etc.) that may be more relevant to your project. Moreover, size and quality are not always correlated. 

Defining a budget 

Even if a low price is an important criterion, it should not be the major one. If a services provider seems more relevant and more competent, although more expensive, it may be worthwhile to concede to a more substantial investment, which may protect further from additional costs (due to deadlines issues, or even a change of services provider during the study).

Rely on trust... or on a previous experience!

Delays in the preclinical phases can be extremely damaging to small structures and may even jeopardize their survival. Therefore, all R&D providers must be considered trustworthy partners. When presenting the project, he must be critical of the provided elements and challenge the protocol that you are submitting to him. Good advice will save time and thus money, and a realistic time frame and a presentation of the risks involved are must-haves. And of course, getting insights from a preliminary experience is likely to help to choose.

Experience, certifications, and regulatory compliance

Depending on the stage of the project, certifications and compliance with processes might be required. It is mandatory to acquire good practices as soon as possible in the drug development process.
 
 
favicon large un peu plus-1